Prescription of Sacubitril/Valsartan in Patients with Heart Failure and Reduced Ejection Fraction Attending an Outpatient Heart Failure Clinic

QR Code

Prescription of Sacubitril/Valsartan in Patients with Heart Failure and Reduced Ejection Fraction Attending an Outpatient Heart Failure Clinic

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	M Rizzo, I Colomer-Asenjo, M Sutil-Vega, G Cabello-Molina, S Marín-López, F Taibi-Hajjami, C Roca-Guerrero, D García-Vega, M Panelo-Rubio, M Bonastre-Thio, A Martínez-Rubio
Format:	article
Langue:	EN
Publié:	Radcliffe Medical Media 2020
Sujets:	Diseases of the circulatory (Cardiovascular) system RC666-701
Accès en ligne:	https://doaj.org/article/4ed32ea019ae4bcabe0fcae76c2c7571
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Tolerability Profile and Discontinuation Causes of Sacubitril/Valsartan Treatment in ‘Real-life’ Patients with Heart Failure and Reduced Ejection Fraction
par: M Rizzo, et autres
Publié: (2020)

Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
par: Mauro Gori, et autres
Publié: (2021)

Renal protective effect of sacubitril/valsartan in patients with heart failure
par: Hui-Ling Hsieh, et autres
Publié: (2021)

Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
par: Domingo Pascual-Figal, et autres
Publié: (2021)

Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data
par: Cuthbert JJ, et autres
Publié: (2020)

The effectiveness and tolerability of switching Indian patients from sacubitril/valsartan, ARNI to perindopril in heart failure with reduced ejection fraction. [Efficient study]
par: Pankaj Jariwala, et autres
Publié: (2021)

The impact of discontinuation of sacubitril–valsartan and shifting to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in patients with heart failure with reduced ejection fraction
par: Osama A. Amin, et autres
Publié: (2021)

Benefits and adverse effects of sacubitril/valsartan in patients with chronic heart failure: A systematic review and meta‐analysis
par: Elodie Charuel, et autres
Publié: (2021)

An Evaluation of the Initiation and Use of Sacubitril/Valsartan in an Inpatient Heart Failure Population: A Retrospective Medication Use Evaluation
par: Tara Snyder, et autres
Publié: (2019)

Cardioprotective effects of early intervention with sacubitril/valsartan on pressure overloaded rat hearts
par: Xiaofei Li, et autres
Publié: (2021)

Classification of heart failure: A farewell to ejection fraction?
par: Thomas F. Lüscher
Publié: (2021)

Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction
par: Maria Vincenza Polito, et autres
Publié: (2020)

Suppression of Tumourigenicity 2 in Heart Failure With Preserved Ejection Fraction
par: Veronika Zach, et autres
Publié: (2020)

Role of nutritional supplementation in heart failure with reduced ejection fraction
par: Yash Paul Sharma, et autres
Publié: (2021)

Sacubitril/valsartan in real-life clinical practice
par: Yüksel Çavuşoğlu
Publié: (2021)

Pheochromocytoma: An overlooked reversible cause of heart failure with reduced ejection fraction
par: Ali Çoner, et autres
Publié: (2021)

Determinants of gait speed in patients with heart failure with reduced ejection fraction
par: Aylin Tanrıverdi, et autres
Publié: (2021)

Effects of Exercise Training on Cardiac Function in Heart Failure with Preserved Ejection Fraction
par: Hidekatsu Fukuta
Publié: (2020)

Heart Failure With Mid-range or Recovered Ejection Fraction: Differential Determinants of Transition
par: Davide Margonato, et autres
Publié: (2020)

Delayed repolarization and ventricular tachycardia in patients with heart failure and preserved ejection fraction.
par: Jae Hyung Cho, et autres
Publié: (2021)

Body Mass Index: An Effective Predictor of Ejection Fraction Improvement in Heart Failure
par: Li-fang Ye, et autres
Publié: (2021)

A profile of heart failure with preserved ejection fraction in a teaching institute
par: Gaurav Aggarwal, et autres
Publié: (2021)

Features of heart failure with preserved ejection fraction (HFpEF) in diabetic patients with resistant hypertension
par: M. A. Manukyan, et autres
Publié: (2021)

Optimizing Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction During Hospitalization
par: Neal M Dixit, et autres
Publié: (2021)

The New Heart Failure Association Definition of Advanced Heart Failure
par: Marco Metra, et autres
Publié: (2019)

Sacubitril/valsartan alleviates myocardial fibrosis in diabetic cardiomyopathy rats
par: Jiao Ai, et autres
Publié: (2021)

Transcriptomic Research in Heart Failure with Preserved Ejection Fraction: Current State and Future Perspectives
par: Sebastian Rosch, et autres
Publié: (2020)

Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?
par: Sebastiaan HC Klaassen, et autres
Publié: (2020)

Left ventricular fibrosis and hypertrophy are associated with mortality in heart failure with preserved ejection fraction
par: Pankaj Garg, et autres
Publié: (2021)

Effects of beta-blockers on heart failure with preserved ejection fraction: a meta-analysis.
par: Feng Liu, et autres
Publié: (2014)

Interatrial shunt devices for heart failure with normal ejection fraction: a technology update
par: Cuthbert JJ, et autres
Publié: (2017)

Evaluation of potential underuse of cardiac resynchronization therapy for heart failure with reduced ejection fraction
par: Makoto Takano, et autres
Publié: (2021)

Remote Hind-Limb Ischemia Mechanism of Preserved Ejection Fraction During Heart Failure
par: Rubens P. Homme, et autres
Publié: (2021)

Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
par: Steffen Pabel, et autres
Publié: (2021)

Heart failure clinical care analysis uncovers risk reduction opportunities for preserved ejection fraction subtype
par: Rebecca T. Levinson, et autres
Publié: (2021)

Higher Serum Phosphorus Is Not an Independent Risk Factor of Mortality in Heart Failure with Reduced Ejection Fraction
par: Partyka Robert, et autres
Publié: (2021)

Readmissions, Death and Its Associated Predictors in Heart Failure With Preserved Versus Reduced Ejection Fraction
par: Wan Ting Tay, et autres
Publié: (2021)

A study of association between heart failure with preserved ejection fraction with hypertension and diabetes mellitus
par: Swapan Sarkar, et autres
Publié: (2021)

Association of serum total bilirubin levels with diastolic dysfunction in heart failure with preserved ejection fraction
par: Zheng,Huan, et autres
Publié: (2014)

Hidden in Heart Failure
par: Douglas Ewan Cannie, et autres
Publié: (2019)